8-KMaterial AgreementsFinancial EventsExhibits & Filings

CENTENE CORP 8-K Report, Material Agreement (Jul 1, 2021)

Filed July 1, 2021For Securities:CNC

Summary

Centene Corporation (CNC) has filed an 8-K report detailing the completion of a $1.8 billion underwritten public offering of 2.450% Senior Notes due 2028. The primary purpose of this offering is to finance a portion of the cash consideration required for Centene's previously announced acquisition of Magellan Health Inc. The closing of the note offering is not contingent on the completion of the Magellan acquisition, providing Centene with capital flexibility. If the acquisition does not proceed, the net proceeds will be allocated to debt repayment and general corporate purposes. These senior unsecured notes rank equally with existing and future senior indebtedness, and are senior to subordinated debt, but effectively junior to secured indebtedness. The notes carry a maturity date of July 15, 2028, with semi-annual interest payments. The company retains the option to redeem the notes under specific conditions, including a change of control provision that would trigger a mandatory offer to purchase the notes at 101% of the principal amount. This financing move is a significant step in Centene's strategic growth plans, particularly its pursuit of the Magellan Health acquisition.

Key Highlights

  • 1Centene Corporation completed a $1.8 billion offering of 2.450% Senior Notes due 2028.
  • 2Proceeds are intended to finance the acquisition of Magellan Health Inc.
  • 3The note offering's closing is independent of the Magellan acquisition's closing.
  • 4If the acquisition fails, proceeds will be used for debt repayment and general corporate purposes.
  • 5The notes are senior unsecured obligations, maturing on July 15, 2028.
  • 6Redemption options exist, including a change of control provision triggering a 101% purchase offer.
  • 7The offering was made under an effective automatic shelf registration statement on Form S-3ASR.

Frequently Asked Questions

The primary use of the net proceeds from the $1.8 billion note offering is to finance a portion of the cash consideration for Centene's acquisition of Magellan Health Inc., as well as related fees and expenses.

If the Magellan Health acquisition is not completed, Centene expects to use the net proceeds from this offering for debt repayment and general corporate purposes.

The notes carry a fixed interest rate of 2.450% and will mature on July 15, 2028. Interest will be paid semi-annually.

These notes are senior unsecured obligations, ranking equally with Centene's existing and future senior indebtedness, and senior to any subordinated indebtedness. However, they are effectively junior to any secured indebtedness to the extent of the value of the collateral securing such debt.

Yes, Centene may redeem the notes at its option under specific conditions before maturity. Additionally, if certain 'changes of control' occur, Centene will be required to make an offer to repurchase the notes at 101% of the principal amount, plus accrued interest.